Well, I accept that where this company sits right now is the value that the market assigns it but it is not my assessment. My role as an investor to identify mismatches between market valuations and mine and invest accordingly. If I wait to invest until 50-100M of EBITDA is baked into the results, the shares will already be trading at $15-$20. So on that basis, I purchased more shares after the October 1st qrt update and some more last Friday after the positive presentation by the CEO.
I can't help but think that the market is facturing in another $250M loss for the FY instead of $50-100M profit.
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-23
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.56 |
Change
0.000(0.00%) |
Mkt cap ! $387.9M | |||
| Open | High | Low | Value | Volume |
| $4.55 | $4.64 | $4.53 | $551.8K | 120.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2458 | $4.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.57 | 4730 | 4 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| MYX (ASX) Chart |